Kensuke Hori

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 4

Top Topics

Endometrial Cancer

Top Venues

Journal of gynecologic oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Daisuke Aoki, Tsutomu Tabata, Satoshi Yanagida, Toshiaki Nakamura, Asumi Okumura, Junzo Hamanishi, Kenichi Harano, Kosei Hasegawa, Takeshi Hirasawa, Kensuke Hori, Shinichi Komiyama, Motoki Matsuura, Hidekatsu Nakai, Hiroko Nakamura, Jun Sakata, Kazuhiro Takehara, Munetaka Takekuma, Yoshihito Yokoyama, Yoichi Kase, Shuuji Sumino, Junpei Soeda, Ai Kato, Ajit Suri, Aikou Okamoto, Toru Sugiyama
Niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer: final results of a multicenter phase 2 study. Journal of gynecologic oncology 35 (5) (2024)
Tomomi Egawa-Takata, Yutaka Ueda, Kimihiko Ito, Kensuke Hori, Tadahiro Shoji, Takayuki Nagasawa, Shin Nishio, Kimio Ushijma, Nishino Koji, Takayuki Enomoto, Akira Kikuchi, Shigeru Honma, Tetsuro Ohishi, Muneaki Shimada, Yuji Takei, Hiroyuki Fujiwara, Hiroshi Tanabe, Aikou Okamoto, Yukihiro Nishio, Tomomi Yamada, Tadashi Kimura
Adjuvant Chemotherapy for Endometrial Cancer (ACE) trial: A randomized phase II study for advanced endometrial carcinoma. Cancer science 113 (5) (2022)
Kensuke Hori, Shin Nishio, Kimio Ushijma, Yuka Kasamatsu, Asumi Okumura, Kazuhiro Takehara, Kimihiko Ito
A phase II, open-labeled, single-arm study of dose-dense paclitaxel plus carboplatin in advanced or recurrent uterine endometrial cancer treatment: a KCOG-G1303, DOENCA trial. Journal of gynecologic oncology 32 (4) (2021)
Aikou Okamoto, Asumi Okumura, Toshiaki Nakamura, Satoshi Yanagida, Junzo Hamanishi, Kenichi Harano, Kosei Hasegawa, Takeshi Hirasawa, Kensuke Hori, Shinichi Komiyama, Motoki Matsuura, Hidekatsu Nakai, Hiroko Nakamura, Jun Sakata, Tsutomu Tabata, Kazuhiro Takehara, Munetaka Takekuma, Yoshihito Yokoyama, Yoichi Kase, Shuuji Sumino, Junpei Soeda, Ajit Suri, Daisuke Aoki, Toru Sugiyama
Phase 2 single-arm study on the efficacy and safety of niraparib in Japanese patients with heavily pretreated, homologous recombination-deficient ovarian cancer. Journal of gynecologic oncology 32 (2) (2020)